Since January 21 GILD (NasdaqGS) has been conveying optimistic changes: $62.63 turned into $84.00 as of April 30. However, a steep 5% decline occurred on the first day of May by indicating stock opening at $79.97, then closed at $79.95. Those who bought the stock should not be worried about the short term loss since an enormous amount of funds must have been invested in biotech projects to fight the current pandemic. The company has long enough experience in creating medicines and technology to cope with serious diseases.
Its net income fell by 1.3% in December 2019 report. Nevertheless, total liabilities have been shrinking since 2017. One may simply see its balance sheet has increased total stockholders’ equity which positively affects its share price.